The probable role of pyroptosis and high levels of IL1- β in the pathogenesis of severe COVID-19 provided the rational to development of clinical trials to address the efficacy and safety of anti-IL-1 targeted therapy [23]. The gene discussed is IL1B; the disease is COVID-19.